Gufic Biosciences (509079) Q3 24/25 earnings summary

Executive summary

• Indore manufacturing facility commenced production post-validation in October 2024, with scale-up expected in coming quarters and significant future capacity potential.

• Focus on innovation, market expansion, and high-quality pharmaceutical solutions, with key milestones in critical care, fertility, and specialty segments.

• Criticare Division strengthened hospital partnerships and advanced antimicrobial portfolio, focusing on multidrug-resistant infections.

• Ferticare Division launched innovative ART solutions, including Guficin Alpha for recurrent implantation failure and Supergraf for IVF.

• Aesthaderm & Nurocare expanded training, launched new products, and published a comparative study showing Stunnox®'s efficacy.

Financial highlights

• Q3 FY25 revenue: ₹207.8 Cr vs ₹201.8 Cr in Q3 FY24; EBITDA: ₹35.8 Cr (17.23%) vs ₹36.9 Cr (18.29%); PAT: ₹19.4 Cr (9.34%) vs ₹22.3 Cr (11.05%).

• Nine months FY25 revenue: ₹614.8 Cr vs ₹616.7 Cr; EBITDA: ₹111.6 Cr vs ₹112.9 Cr; EBITDA margin: 18.15%.

• FY24 revenue: ₹808.8 Cr, EBITDA: ₹148.0 Cr (18.3% margin), PAT: ₹86.1 Cr (10.6% margin).

• Consolidated Q3 FY25 revenue: ₹20,779.39 lakhs, up from ₹20,177.79 lakhs in Q3 FY24; net profit: ₹1,930.52 lakhs vs ₹2,225.71 lakhs.

• Basic and diluted EPS for Q3 FY25 was ₹1.93, compared to ₹2.23 in Q3 FY24.

Outlook and guidance

• Indore facility expected to reach 25%-30% capacity utilization next year, 50%-60% the year after, with revenue projected at ₹150 Cr in 3-5 years and break-even in 4-5 quarters.

• Focus on scaling up Indore for regulated markets (US/EU), expanding product pipeline, and international expansion.

• Margin pressure anticipated for next 2-3 quarters due to Indore ramp-up; improvement expected post-2026.

• Policy amendments and new subsidiary incorporations indicate ongoing alignment with regulatory changes and international expansion.